Ginkgo Bioworks Holdings (DNA) Restructuring Costs (2024 - 2025)
Ginkgo Bioworks Holdings' (DNA) quarterly Restructuring Costs came in at $706000.0 in Q4 2025, down 83.02% YoY from $4.2 million in Q4 2024, and down 59.54% on a QoQ basis from $1.7 million in Q3 2025.
Powered by 
Analysis
Ginkgo Bioworks Holdings (DNA) Restructuring Costs (2024 - 2025) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 2 years of Restructuring Costs data on file, last reported at $706000.0 in Q4 2025.
- Quarterly Restructuring Costs fell 83.02% year-over-year to $706000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $6.1 million (down 78.64% YoY) and the FY2025 annual result came in at $11.4 million, down 52.85% from the prior year.
- Restructuring Costs slipped to $706000.0 in Q4 2025, from $1.7 million in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $17.1 million in Q2 2024 to a low of $706000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.70 Bn | 58.52 Bn | 1.37 Bn |
| 4 | Moderna | 57.56 Bn | 52.42 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 40.16 Bn | 35.06 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.63 Bn | 32.32 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.63 Bn | 27.79 Bn | - |
| 9 | Insmed | 27.73 Bn | 26.57 Bn | 358.27 Mn |
| 10 | Ginkgo Bioworks Holdings | 430.38 Mn | 345.84 Mn | 18.44 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 706,000.00 |
| Sep 30, 2025 | 1.75 Mn |
| Jun 30, 2025 | 3.60 Mn |
| Mar 31, 2025 | 4.50 Mn |
| Dec 31, 2024 | 4.16 Mn |
| Sep 30, 2024 | 2.95 Mn |
| Jun 30, 2024 | 17.07 Mn |